hotspot -WSS

hotspot

author：explore 2025-10-06 16:29:02 - browse：151

Allergan, Dom Smith/STAT

It wasn’t supposed to work out this way for Brent Saunders.

Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： What PEPFAR has meant on the ground in Ukraine

WSS

AI models in health care face new federal disclosure requirements

Abbott's new heart device gets FDA advisory panel nod

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

What PEPFAR has meant on the ground in Ukraine

FDA needs staff influx to meet gene therapy needs, Marks says

Artificial intelligence use in health care faces greater scrutiny in 2024

knowledge

hotspot

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

Americans' trust in science, scientist continues decline: Report

Novavax promises a turnaround & Lilly roils the obesity market

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Wildfire smoke exposes gaps in outdoor worker protections

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

What does generative AI mean for health care? We asked experts

STAT letters to the editor on burnt

hotspot

Chemotherapy shortages won’t get better under Biden’s latest plan

Leukemia patients are helped by Syndax's new type of therapy

The woman behind the Dana Farber

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Chemotherapy shortages won’t get better under Biden’s latest plan

Roche to buy Carmot Therapeutics, developer of obesity drugs

hotspot

explore

entertainment

focus